Why is Sanofi stock sliding to a 52-week low today?
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Sanofi Par Prf (AVEPp)
Sanofi Par Prf stock price live, this page displays EPA AVEPp stock exchange data. View the AVEPp premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Sanofi Par Prf real time stock price chart below.
What Is the Sanofi Par Prf Stock Price Today?
The Sanofi Par Prf stock price today is 525.00.
What Is the Stock Symbol for Sanofi Par Prf?
The stock symbol for Sanofi Par Prf is "AVEPp."
What Stock Exchange Does Sanofi Par Prf Trade On?
Sanofi Par Prf is listed and trades on the Paris stock exchange.
Is Sanofi Par Prf a Good Stock to Buy?
Determining whether Sanofi Par Prf—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AVEPp quote. (ISIN: FR0000140022)
What Is the Sanofi Par Prf Stock Price Today?
The Sanofi Par Prf stock price today is 525.00.
What Is the Stock Symbol for Sanofi Par Prf?
The stock symbol for Sanofi Par Prf is "AVEPp."
What Stock Exchange Does Sanofi Par Prf Trade On?
Sanofi Par Prf is listed and trades on the Paris stock exchange.
Is Sanofi Par Prf a Good Stock to Buy?
Determining whether Sanofi Par Prf—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AVEPp quote. (ISIN: FR0000140022)
525.00
+6.00(+1.16%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
500.02
525.00
52 wk Range
500.02
615.00
Trading near 52-week Low
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
500.02525.00
52 wk Range
500.02615.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AVEPp Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Prominent player in the Pharmaceuticals industry
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Earnings
Latest Release
Jul 30, 2026
EPS / Forecast
0.28 / --
Revenue / Forecast
12.3B / --
Compare AVEPp to Peers and Sector
Metrics to compare | AVEPp | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAVEPpPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | 20.8x | −0.4x | |
PEG Ratio | 0.00 | −0.38 | 0.00 | |
Price/Book | 0.0x | 1.8x | 2.6x | |
Price / LTM Sales | 0.0x | 2.8x | 3.0x | |
Upside (Analyst Target) | 0.0% | 13.6% | 56.4% | |
Fair Value Upside | Unlock | 19.3% | 7.9% | Unlock |
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine’s AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV’574, for treatment of ulcerative colitis and Crohn’s disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
People Also Watch
FAQ
What Is the Sanofi Par Prf (AVEPp) Stock Price Today?
The Sanofi Par Prf stock price today is 525.00 EUR.
What Stock Exchange Does Sanofi Par Prf Trade On?
Sanofi Par Prf is listed and trades on the Paris Stock Exchange.
What Is the Stock Symbol for Sanofi Par Prf?
The stock symbol for Sanofi Par Prf is "AVEPp."
What Is the Sanofi Par Prf Market Cap?
As of today, Sanofi Par Prf market cap is 84.06B EUR.
What Is Sanofi Par Prf's Earnings Per Share (TTM)?
The Sanofi Par Prf EPS (TTM) is 3.25.
From a Technical Analysis Perspective, Is AVEPp a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Sanofi Par Prf Stock Split?
Sanofi Par Prf has split 0 times.
How Many Employees Does Sanofi Par Prf Have?
Sanofi Par Prf has 74846 employees.
What is the current trading status of Sanofi Par Prf (AVEPp)?
As of Oct 02, 2026, Sanofi Par Prf (AVEPp) is trading at a price of 525.00 EUR, with a previous close of 519.00 EUR. The stock has fluctuated within a day range of 500.02 EUR to 525.00 EUR, while its 52-week range spans from 500.02 EUR to 615.00 EUR.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.